Headlines about Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biohaven Pharmaceutical Holding Co earned a news impact score of 0.15 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.994214710365 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern’s rankings:

BHVN has been the topic of several analyst reports. William Blair initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They set an “outperform” rating and a $46.00 target price on the stock. Barclays PLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They set an “overweight” rating and a $30.00 target price on the stock. Piper Jaffray Companies initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They set an “overweight” rating and a $21.00 target price on the stock. Morgan Stanley initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Wednesday, May 31st. They set an “overweight” rating on the stock. Finally, Needham & Company LLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They set a “buy” rating and a $30.00 target price on the stock. Five research analysts have rated the stock with a buy rating, Biohaven Pharmaceutical Holding Co presently has a consensus rating of “Buy” and an average target price of $31.75.

Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 24.40 on Friday. The firm’s 50-day moving average is $25.00 and its 200 day moving average is $23.84. Biohaven Pharmaceutical Holding Co has a 52-week low of $17.00 and a 52-week high of $29.50. The firm’s market capitalization is $872.25 million.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Biohaven Pharmaceutical Holding Co (BHVN) Stock Price” was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-biohaven-pharmaceutical-holding-co-bhvn-stock-price.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.